Skip to content
10-Q

Quarterly Report

BICARA THERAPEUTICS INC. BCAX

0002023658-25-000039

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 8, 2025 54.54M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $462.07M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $489.71M
Current Liabilities Q1 2025 · Mar 31, 2025 $19.12M
Current Liabilities Q1 2025 · Dec 31, 2024 $17.99M
Total Liabilities Q1 2025 · Mar 31, 2025 $19.12M
Total Liabilities Q1 2025 · Dec 31, 2024 $18.12M
Current Assets Q1 2025 · Mar 31, 2025 $470.75M
Current Assets Q1 2025 · Dec 31, 2024 $502.53M
Total Assets Q1 2025 · Mar 31, 2025 $478.08M
Total Assets Q1 2025 · Dec 31, 2024 $510M
Rd Expense Q1 2025 · Mar 31, 2025 $34.3M
Rd Expense Q1 2025 · Mar 31, 2024 $12M
Shares Diluted Q1 2025 · Mar 31, 2024 660.29K sh
Capex Q1 2025 · Mar 31, 2024 $4K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$14.59M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$160.08M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$148.77M
Eps Diluted Q1 2025 · Mar 31, 2024 −$18.94
Eps Basic Q1 2025 · Mar 31, 2024 −$18.94
Sga Expense Q1 2025 · Mar 31, 2024 $3.34M
Net Income Q1 2025 · Mar 31, 2024 −$12.51M
Operating Income Q1 2025 · Mar 31, 2024 −$15.37M